in

References

  1. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42:1206. [abstract]
  2. Salerno SM, Jackson JL, Berbano EP. Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis. Arch Intern Med. 2005; 165:1686. [Full text]
  3. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51:1403. [Full text]
  4. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008; 168:1159. [Full text]
  5. Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Rep. 2007; 9:353. [abstract]
  6. Kahn SL, Angle JF. Adrenal vein sampling. Tech Vasc Interv Radiol. 2010; 13:110. [abstract]
  7. Quinkler M, Stewart PM. Treatment of primary aldosteronism. Best Pract Res Clin Endocrinol Metab. 2010; 24:923. [abstract]
  8. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003; 16(11 Pt 1):925. [abstract]
  9. Ouzan J, Pérault C, Lincoff AM, Carré E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002; 15(4 Pt 1):333. [abstract]
  10. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003; 361:117. [abstract]
  11. [No authors listed] Retraction--Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet. 2009; 374:1226. [article information; no abstract]
  12. Messerli FH, Staessen JA, Zannad F. Of fads, fashion, surrogate endpoints and dual RAS blockade. Eur Heart J. 2010; 31:2205. [abstract]
Copyright © 2010, 2011  Perelman School of Medicine at the University of Pennsylvania Office of Continuing Medical Education & BestPractice CPD, LLC®. All rights reserved.